

Responding patient images from the 75 patient snapshot in anti-PD1 failed melanoma

 *Injected lesions*

 *Not injected lesions*

*Months on study are approx., and relate to
time from the screening/baseline scan*

Patient 4405-2007: Prior Keytruda, Yervoy/Opdivo


Disease presentation type: Progressed on combined anti-CTLA-4/anti-PD1 Stage IV M1b




Baseline



5 months



19 months



 Injected




 Un-injected

Patient 4405-2007 contd.

Baseline

5 months


19 months





Patient 1122-2031: Prior Yervoy/Opdivo

Disease presentation type: Progressed on combined anti-CTLA-4 and anti-PD1 Stage IVM1c

Baseline



2 months



 *Injected*

 *Un-injected*

Patient 1121-2011: Prior Opdivo (adjuvant), Keytruda (1L)


Disease presentation type: Progressed on anti-PD1 Stage IVM1c



Baseline







9 months







Patient 1121-2011 contd.





Baseline



2 months



9 months




 *Injected*


 *Un-injected*

Patient 1121-2011 contd.


Baseline



2 months



9 months



 Injected

 Un-injected


Patient 1121-2013: Prior Keytruda

Disease presentation type: Progressed on anti-PD1 Stage IVM1c

Baseline



4 months



16 months



 *Injected*

 *Un-injected*

Patient 4401-2021: Prior Tafinlar/Mekinist, Keytruda




Disease presentation type: Prior BRAF/MEK and progressed on anti-PD1 Stage IVM1c

Baseline

15 months

Baseline

15 months




○ Injected

○ Un-injected


Patient 1156-2001: Prior Keytruda

Disease presentation type: Progressed on anti-PD1 stage IVM1c (near PR; on treatment)




Baseline



8 months



14 months



 Injected

 Un-injected

Patient 4403-2012: Prior Yervoy/Opdivo

Disease presentation type: Progressed on anti-PD1 and anti-CTLA4 Stage IV M1b







Baseline

2 months

4 months

6 months

13 months




 Injected

 Un-injected

Note: The second row lesion may be benign


Patient 4401-2013: Prior Yervoy, Opdivo

Disease presentation type: Progressed on anti-PD1 and anti-CTLA-4 Stage IVM1b



 Injected  Un-injected

Note: Also a number of small pelvic nodes, not shown



Patient 1122-2032: Prior Opdivo, Yervoy

Disease presentation type: Progressed on anti-PD1 and CTLA-4 Stage IV M1b





Baseline

2 months

4 months

11 months



 Injected

 Un-injected

Patient 1120-2001: Prior Keytruda, Opdivo/bempeg/NKTR 262, Yervoy/Opdivo

Disease presentation type: Progressed on multiple immunotherapies Stage IV M1a (PR; on treatment)





Baseline

3 months

5 months

12 months



 *Injected*  *Un-injected*





Patient 4403-2013: Prior Keytruda

Disease presentation type: Progressed on anti-PD1 Stage IVM1a

Baseline

2 months

13 months



NOTE:
Day 57 top 2 column
different slices through
abdomen due to
different breath hold



Injected









Un-injected

Patient 4403-2013 contd.

Baseline

2 months

13 months




 *Injected*


 *Un-injected*

Patient 4403-2013 contd.




Baseline



2 months



13 months



THIS SCAN DID NOT EXTEND
DISTALLY TO THE KNEES


NUMEROUS OTHER LESIONS
NOT SHOWN

 *Injected*

 *Un-injected*

Patient 1126-2001: Prior Opdivo

Disease presentation type: Progressed on prior adjuvant anti-PD1 Stage IIIc



Patient 3410-2001: Prior Keytruda

Disease presentation type: Progressed on adjuvant anti-PD1 Stage IVM1a




Baseline

4 months

8 months

17 months



 *Injected*  *Un-injected*





Patient 3410-2001 contd.

Baseline

4 months

8 months

17 months




 *Injected*

 *Un-injected*

Patient 1122-2012: Prior Opdivo

Disease presentation type: Progressed on anti-PD1 Stage IIIc



 *Injected*  *Un-injected*

Patient 1122-2027: Prior Keytruda

Disease presentation type: Progressed on adjuvant anti-PD1 Stage IIIc

 Injected

 Un-injected




Baseline

2 months

4 months

5 months

15 months



Patient 1122-2034: Prior Keytruda


Disease presentation type: Progressed on anti-PD1 Stage IIIc

Baseline

2 months

4 months

12 months



 *Injected*

 *Un-injected*

Patient 1122-2015: Prior Keytruda

Disease presentation type: Progressed on adjuvant anti-PD1 Stage IIIc

Baseline



4 months



11 months



 *Injected*

 *Un-injected*






Patient 1122-2016: Prior Opdivo

Disease presentation type: Progressed on adjuvant anti-PD1 therapy Stage IIIc

Baseline

4 months

9 months



 Injected





 Un-injected

Patient 1122-2016: Contd.

Baseline

4 months

9 months



 *Injected*  *Un-injected*

Patient 1119-2008: Prior Keytruda












Disease presentation type: Progressed on adjuvant anti-PD1 Stage IIIc

Baseline

2 months

8 months

20 months



○ Injected

○ Un-injected

Patient 1121-2008: Prior Keytruda

Disease presentation type: Progressed on adjuvant anti-PD1 Stage IIIc

Baseline



7 months



Patient 1121-2005: Prior Keytruda

Disease presentation type: Progressed on adjuvant anti-PD1 Stage IIIc

Baseline

2 months

5 months



Patient 1103-2004: Prior Keytruda

Disease presentation type: Progressed on adjuvant anti-PD1 Stage IIIc



Baseline



4 months



11 months



 *Injected*

 *Un-injected*


Patient 4403-2007: Prior Keytruda

Disease presentation type: Progressed on adjuvant anti-PD1 Stage IIIb




Baseline



8 months



23 months



 *Injected*

 *Un-injected*





Patient 1117-2006: Prior Keytruda

Disease presentation type: Progressed on adjuvant anti-PD1 Stage IIIb

Baseline

2 months

5 months




 Injected

 Un-injected


Patient 1122-2030: Prior Keytruda

Disease presentation type: Progressed on adjuvant anti-PD1 Stage IIIb


Baseline



2 months



9 months



 *Injected*

 *Un-injected*